Compare TRIB & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRIB | LSTA |
|---|---|---|
| Founded | 1992 | 1980 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3M | 20.9M |
| IPO Year | N/A | N/A |
| Metric | TRIB | LSTA |
|---|---|---|
| Price | $0.98 | $2.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | ★ 83.5K | 23.8K |
| Earning Date | 03-23-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $61,555,000.00 | $1,070,000.00 |
| Revenue This Year | $13.51 | N/A |
| Revenue Next Year | $13.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 8.31 | N/A |
| 52 Week Low | $0.48 | $1.81 |
| 52 Week High | $3.44 | $4.20 |
| Indicator | TRIB | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 46.06 | 43.92 |
| Support Level | $1.04 | $1.85 |
| Resistance Level | $1.22 | $2.15 |
| Average True Range (ATR) | 0.11 | 0.13 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 23.48 | 48.44 |
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.